This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-31 and is reviewed periodically as new material appears.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Modafinil is commercially available in 100 mg and 200 mg oral tablet forms. Additionally, it is offered as the (R)-enantiomer, known as armodafinil, and as a prodrug named adrafinil. Armodafinil is available in 50, 150, 200, and 250 mg tablets. A 100 mg dose of modafinil has been said to be essentially equivalent to a 50 mg dose of armodafinil in terms of drug levels.
=== 14 January === The JDF claimed to have killed hundreds of RSF militants, destroyed 262 vehicles, and captured 21 militants and 67 vehicles during clashes in Al-Malha and Halaf in North Darfur. At least 18 people were killed in attacks by the Sudan Shield Forces on the Shukaba camp and Camp 16 in Gezira State.
Access to graduate medical training programs such as residencies is a competitive process known as "the Match". After the interview period is over, students submit a "rank-order list" to a centralized matching service that depends on the residency program they are applying for:
Sources: en.wikipedia.org
Like HMB, creatine is an ergogenic aid that appears to improve anaerobic capacity and muscle mass in individuals who perform high-intensity exercise. When supplemented together, studies have suggested that creatine produces a synergistic effect that can augment HMB-induced improvements on aerobic and anaerobic performance, endurance, and lean body mass in exercise programs of sufficient intensity, relative to HMB alone. In 2006, only about 2% of college student athletes in the United States used HMB as a dietary supplement. As of 2017, HMB has found widespread use as an ergogenic supplement among athletes. As of 2018, HMB has not been banned by the National Collegiate Athletic Association, World Anti-Doping Agency, or any other prominent national or international athletic organization.
Hannibal had a history of the Punic Wars produced, and ordered it to be kept in the temple of Juno Lacinia in Crotone so that the Romans could not falsify the history of the war. Plutarch drew from that source. In the summer of 204 BCE the Romans arrived in Calabria and enslaved the Bruttians to punish their rebellion. Vast estates were requisitioned and assigned to members of the Roman aristocracy. During the Second Punic War (218–201 BCE) the Bruttii allied with Hannibal, who sent Hanno, one of his commanders, to Calabria. Hanno twice marched toward Capua (in Campania) with Bruttian soldiers to take them to Hannibal's headquarters there, but he was twice defeated. When his campaign in Italy came to an end, Hannibal took refuge in Calabria, whose steep mountains provided protection against the Roman legions. He set up his headquarters in Kroton and stayed there for four years until he was recalled to Carthage. The Romans fought a battle with him near Kroton, but its details are not recorded. Many Calabrian cities surrendered to the Romans and Calabria was put under a military commander.
In 1933, Norway, which occupied part of Eastern Greenland, accepted a ruling of the Permanent Court of International Justice affirming Danish sovereignty over all of Greenland and renounced its claim. The 1953 Constitution of Denmark ended Greenland's status as a colony, integrating it fully into the Danish state as a regular county, as part of decolonization efforts and with the consent of the Greenland Provincial Council. In the 1979 Greenlandic home rule referendum, Denmark granted home rule to Greenland, leading to the establishment of a local government authority with responsibility for local matters, but Greenland remains part of the Kingdom of Denmark, with the central government in Copenhagen solely responsible for defence and foreign policy. As part of the Nordic region and the Kingdom of Denmark, Greenland is an associate member of the Nordic Council. Greenland is one of the Overseas Countries and Territories of the EU. Greenlanders are Danish citizens and therefore also EU citizens. In 2009, Greenland was recognised by the Kingdom of Denmark and under international law as a people entitled to external self-determination. Most political parties in Greenland favour independence from Denmark as a long-term goal, with a draft constitution for an independent Greenlandic state presented by lawmakers in 2023, but the majority does not favour severing ties with Denmark in the short term.
Sources: en.wikipedia.org
The original Pennsylvania Station was an ornate station building designed by McKim, Mead, and White and considered a masterpiece of the Beaux-Arts style. Completed in 1910, it enabled direct rail access to New York City from the south for the first time. Its head house and train shed were torn down in 1963 at a time of low train ridership, with the rail infrastructure reconstituted as the smaller underground station that survives today. The New York Times editorial board described the demolition of the original station as a "monumental act of vandalism", and its destruction galvanized the modern historic preservation movement. As rail travel increased again in the following decades, the underground station began to operate beyond its design capacity. By 2015, the station handled 650,000 travelers daily (more than the region's three major airports combined) and had become loathed for its cramped, claustrophobic conditions. The 2020s saw the opening of Moynihan Train Hall, a head house that expanded Penn Station into the Farley building, as well as expansion of the LIRR concourse and a new direct entrance from 33rd Street. Plans under development call for reconstruction of the core of the station, with competing proposals regarding the station's relationship to Madison Square Garden under consideration. Looking back on the pace of reconstruction since the announcement of Moynihan Hall in 1999, the Times noted in 2025 that "More than 25 years, five presidencies and four governors later, the plan to rebuild Penn Station is nowhere near completion."
The hydroponic method of plant production by means of suspending the plant roots in a solution of nutrient-rich, oxygenated water. Traditional methods favor the use of plastic buckets and large containers with the plant contained in a net pot suspended from the centre of the lid and the roots suspended in the nutrient solution. The solution is oxygen saturated by an air pump combined with porous stones. With this method, the plants grow much faster because of the high amount of oxygen that the roots receive. The Kratky Method is similar to deep water culture, but uses a non-circulating water reservoir.
Umami peptides are a family of small to medium length polypeptides found in a variety of savoury foods, which impart an umami taste. They are best known from Asian condiments and foods such as soy sauce, fish sauce, oyster sauce, and miso, but are also found in a diverse range of other foods including cheese, stewed or preserved meat products, and Bolete mushrooms. One of the best characterised umami peptides is beefy meaty peptide, originally isolated from beef soup, an eight amino acid peptide with the sequence Lys-Gly-Asp-Glu-Glu-Ser-Leu-Ala which is thought to interact with the T1R1/T1R3 taste receptor complex. There are dozens if not hundreds of umami peptides known, most of which have been little studied in isolation as they typically occur in complex mixtures, which can vary significantly between different foods, brands, and even different batches made the same way. Not all peptides isolated from such mixtures have umami flavour, with some closely related peptides tasting sweet, sour, salty, bitter or kokumi, and often a change in only a single amino acid can be enough to change the flavour entirely. However, the majority of peptides isolated from fermented foods or cooked or preserved meat products tend to have an umami flavour, with trace amounts of peptides with other flavours contributing to the overall flavour profile of the food.
The Israeli Ground Forces (Hebrew: זְרוֹעַ הַיַּבָּשָׁה, romanized: z'róa hibshá, lit. 'The Land Arm') are the army of the Israel Defense Forces (IDF). The current commander of the ground forces is Major General Nadav Lotan. An order from Defense Minister David Ben-Gurion on 26 May 1948 officially set up the Israel Defense Forces as a conscript army formed out of the paramilitary group Haganah, incorporating the militant groups Irgun and Lehi. The Ground Forces have served in all the country's major military operations—including the 1948 Arab–Israeli War, 1956 Suez Crisis, 1967 Six-Day War, 1973 Yom Kippur War, 1976 Operation Entebbe, 1982 Lebanon War, 1987–1993 First Intifada, 2000–2005 Second Intifada, 2006 Lebanon War, and the Gaza War (2008–09). While originally the IDF operated on three fronts—against Lebanon and Syria in the north, Jordan and Iraq in the east, and Egypt in the south—after the 1979 Egyptian–Israeli Peace Treaty, it has concentrated in southern Lebanon and the Palestinian territories, including the First and the Second Intifada. The Ground Forces uses several technologies developed in Israel such as the Merkava main battle tank, Achzarit armoured personnel carrier, the Iron Dome missile defense system, Trophy active protection system for vehicles, and the Galil and Tavor assault rifles. The Uzi submachine gun was invented in Israel and used by the Ground Forces until December 2003, ending a service that began in 1954.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.